Table 2.

Participants characteristics and prevalence of acquired nucleoside reverse transcriptase inhibitor-drug resistant mutations and nonnucleoside reverse transcriptase inhibitor-drug resistant mutations among virologically unsuppressed participants on antiretroviral therapy.

	ADR (DRM) prevalence
Group	N	NRTI, % (95% CI)	NNRTI, % (95% CI)
All participants	138	15.9 (9.8–24.8)	32.6 (24.6–41.8)
Sex
Males	54	19.7 (10.1–33.0)	25.9 (16.4–38.4)
Females	84	11.1 (6.0–19.7)	36.9 (25.8–49.5)
Age (years)
<30	42	25.8 (10.3–51.2)	48.4 (30.4–66.8)
30–39	49	13.7 (4.9–32.9)	27.5 (17.5–40.2)
40–49	29	6.9 (1.6–25.7)	17.2 (7.0–36.5)
50+	18	16.7 (5.0–43.4)	44.4 (26.1–64.4)
Geographical region
South	39	17.9 (7.4–37.4)	23.1 (10.4–43.6)
Central	54	16.7 (8.2–30.7)	33.3 (24.0–44.2)
North	45	13.3 (4.7–32.3)	40.0 (7.9–56.7)
Year of sampling
2013–2015	86	19.8 (11.8–31.2)	26.7 (18.9–36.4)
2016–2018	52	9.6 (3.5–23.7)	15.4 (6.7–31.5)

ADR, acquired drug resistance; CI, confidence intervals; DRM, drug-resistant mutations; NNRTI, nonnucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors.